Author Archives: BSA

New pub @ Drugs in R&D

Predicting Inter-individual Variability During Lipid Resuscitation of Bupivacaine Cardiotoxicity in Rats: A Virtual Population Modeling Study
Matthew McDaniel, Kevin Flores, Belinda Akpa

“Using the exemplar of bupivacaine systemic toxicity and a PBPK-PD model in rats, we have demonstrated how limited physiological data can inform a model that predicts population outcomes of lipid therapy.” 

In this paper, we combined mechanistic modeling, machine learning, and causal analysis to predict resuscitation outcomes across a virtual population and characterize the relative contributions of pharmacokinetic and pharmacodynamic mechanisms to improved survival outcomes. 

EMRLab welcomes Mustafa Farahat!

We’re thrilled to welcome Mustafa Farahat to our team! Mustafa has just finished his first year in the Chemical & Biomolecular Engineering PhD Program at UT-Knoxville. Building on his undergraduate training and research experience in Chemical and Biomedical Engineering at Iowa State University, he will be developing systems models in support of our drug discovery work with Oak Ridge National Laboratory the ATOM consortium.

Hiring for postdoctoral roles at ORNL

Come join our team and contribute to the ATOM consortium as a computational systems biology postdoc at Oak Ridge National Laboratory!

“Purpose: The Biosciences Division of Oak Ridge National Laboratory invites qualified persons to apply for the position of Postdoctoral Research Associate in the area of computational systems physiology and molecular design.

Major Duties/Responsibilities: The position requires collaboration within a multi-disciplinary research environment consisting of experimental biologists, computer scientists, engineers, and mathematicians for a project encompassing multiscale modeling, high performance computing, machine learning, and artificial intelligence in support of molecular design. The skill set of a qualified applicant will be utilized to develop mechanistic systems models for integration with the Accelerating Therapeutics for Opportunities in Medicine (ATOM) platform for drug discovery and in support of the Laboratory’s missions.”
APPLY HERE